Eugene Schneider
Chief Tech/Sci/R&D Officer presso IONIS PHARMACEUTICALS, INC.
Patrimonio netto: 2 M $ in data 31/03/2024
Posizioni attive di Eugene Schneider
Società | Posizione | Inizio | Fine |
---|---|---|---|
IONIS PHARMACEUTICALS, INC. | Chief Tech/Sci/R&D Officer | - | - |
Excellus Health Plan, Inc.
Excellus Health Plan, Inc. Managed Health CareHealth Services Excellus Health Plan, Inc. provides health care and long term care insurance plans for individuals and families, sole proprietors, small businesses, and midsize and large businesses in New York. The company is headquartered in New York, NY. | Chief Tech/Sci/R&D Officer | - | - |
Storia della carriera di Eugene Schneider
Precedenti posizioni note di Eugene Schneider
Società | Posizione | Inizio | Fine |
---|---|---|---|
Biovail Technologies Ltd. | Chief Tech/Sci/R&D Officer | - | - |
SYNAGEVA BIOPHARMA CORP | Chief Tech/Sci/R&D Officer | - | - |
Formazione di Eugene Schneider
University of Medicine & Dentistry of New Jersey | Doctorate Degree |
Statistiche
Distribuzione geografica
Stati Uniti | 6 |
Posizioni
Chief Tech/Sci/R&D Officer | 4 |
Doctorate Degree | 1 |
Settori
Health Technology | 3 |
Consumer Services | 2 |
Health Services | 2 |
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Società collegate
Società quotate in Borsa | 1 |
---|---|
IONIS PHARMACEUTICALS, INC. | Health Technology |
Aziende private | 3 |
---|---|
Excellus Health Plan, Inc.
Excellus Health Plan, Inc. Managed Health CareHealth Services Excellus Health Plan, Inc. provides health care and long term care insurance plans for individuals and families, sole proprietors, small businesses, and midsize and large businesses in New York. The company is headquartered in New York, NY. | Health Services |
Biovail Technologies Ltd. | |
Synageva BioPharma Corp.
Synageva BioPharma Corp. BiotechnologyHealth Technology Synageva BioPharma Corp. is a biopharmaceutical company which focuses on the discovery, development, and commercialization of therapeutic products for patients with life-threatening rare diseases and high unmet medical need. The company is currently evaluating sebelipase alfa in global clinical trials for LAL Deficiency, a lysosomal storage disease associated with liver damage and accelerated atherosclerosis in children and adults, and in infants, premature death often before six months of age. Synageva BioPharma was founded in 1993 and is headquartered in Lexington, MA. | Health Technology |
- Borsa valori
- Insiders
- Eugene Schneider
- Esperienza